Marstacimab clinical trials
Marstacimab is named as an intervention in 5 current clinical trials in our USA, India, China, Turkey, Japan, UK, Spain, Italy, Denmark, Canada, Brazil, Mexico, South Korea, Taiwan, Australia, Israel, France, Germany, Austria and Czechia registers. 4 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Pfizer (4). The most-studied condition is Hemophilia A.
Where Marstacimab is approved
All regulators →Of the three regulators tracked here, the first to approve Marstacimab was the US, on 11 Oct 2024. It is approved in 2 of the 3 regulators tracked here.
- 1 EU orphan designation, most recently for treatment of haemophilia B (13 Dec 2023, withdrawn)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Marstacimab
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Marstacimab works
All drug targets →- Tissue factor pathway inhibitor inhibitor InhibitorTarget: TFPI tissue factor pathway inhibitorChEMBL only
- HemophiliaPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3990039, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13403, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Marstacimab
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Marstacimab. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies NICE TA1073 | Optimised | 24 Jun 2025 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Marstacimab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 2 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: HympavziEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Marstacimab
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Marstacimab across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
2 single-substance products containing Marstacimab on the HPRA medicines list.
- Hympavzi 150 mg solution for injection in pre-filled penPfizer Europe MA EEIG · EU/1/24/1874/002-003
- Hympavzi 150 mg solution for injection in pre-filled syringePfizer Europe MA EEIG · EU/1/24/1874/001
Supply shortages
No entry for Marstacimab in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Marstacimab
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Pfizer | 4 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Marstacimab trials
How many clinical trials are testing Marstacimab?
5 current trials in our USA, India, China, Turkey, Japan, UK, Spain, Italy, Denmark, Canada, Brazil, Mexico, South Korea, Taiwan, Australia, Israel, France, Germany, Austria and Czechia registers name Marstacimab (also registered as PF-06741086) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Marstacimab trials recruiting patients?
Yes. 4 of the 5 trials are recruiting: 3 with sites in USA, 3 with sites in India, 3 with sites in China, 3 with sites in Turkey, 2 with sites in Japan, 2 with sites in UK, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Denmark, 2 with sites in Canada, 2 with sites in Brazil, 2 with sites in Mexico, 2 with sites in South Korea, 2 with sites in Taiwan, 2 with sites in Australia, 2 with sites in Israel, 1 with sites in France, 1 with sites in Germany, 1 with sites in Austria and 1 with sites in Czechia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Marstacimab clinical trials?
Pfizer (4) and Institute of Hematology & Blood Diseases Hospital, China (1). The number in brackets is how many trials each organisation leads.
Is Marstacimab licensed in Ireland?
Yes. The HPRA medicines list includes 2 single-substance products containing Marstacimab, for example Hympavzi 150 mg solution for injection in pre-filled pen (Pfizer Europe MA EEIG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Marstacimab shortage?
Not in the lists we track: Marstacimab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Marstacimab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Marstacimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Marstacimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.